Les échinocandines chez l’enfant Echinocandins in children

Le Guyader, 2007, Antifongiques systémiques en pédiatrie : actualités et perspectives, Arch Pediatr, 14, 1, 10.1016/j.arcped.2006.11.004 Fisher, 2008, Caspofungin for the treatment of pediatric fungal infections, Pediatr Infect Dis J, 27, 1099, 10.1097/INF.0b013e3181937fe0 Lehrnbecher, 2010, Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients, Pediatr Blood Cancer, 55, 229, 10.1002/pbc.22449 VandenBussche, 2010, A clinical review of echinocandins in pediatric patients, Ann Pharmacother, 44, 166, 10.1345/aph.1M139 Lacroix, 2003, Les échinocandines: une nouvelle classe d’antifongiques, Med Mal Infect, 33, 183, 10.1016/S0399-077X(03)00059-3 Pfaller, 2008, In vitro susceptibility of invasive isolates of candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance, J Clin Microbiol, 46, 150, 10.1128/JCM.01901-07 Antachopoulos, 2008, Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus Conidia, Antimicrob Agents Chemother, 52, 321, 10.1128/AAC.00699-07 Pfaller MA, Castanheira M, Messer SA, et al. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age:report from the SENTRY antimicrobial surveillance program (2008–2009). Diagn Microbiol Infect Dis 2010 [in press]. Andes, 2010, In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species, Antimicrob Agents Chemother, 54, 2497, 10.1128/AAC.01584-09 Walsh, 2005, Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents, Antimicrob Agents Chemother, 49, 4536, 10.1128/AAC.49.11.4536-4545.2005 Neely, 2009, Pharmacokinetics and safety of caspofungin in older infants and toddlers, Antimicrob Agents Chemother, 53, 1450, 10.1128/AAC.01027-08 Sáez-Llorens, 2009, Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age, Antimicrob Agents Chemother, 53, 869, 10.1128/AAC.00868-08 Seibel, 2005, Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients, Antimicrob Agents Chemother, 49, 3317, 10.1128/AAC.49.8.3317-3324.2005 Smith, 2009, Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates, Pediatr Infect Dis J, 28, 412, 10.1097/INF.0b013e3181910e2d Benjamin, 2010, Safety and pharmacokinetics of repeat-dose micafungin in young infants, Clin Pharmacol Ther, 87, 93, 10.1038/clpt.2009.200 Hope, 2010, Population pharmacokinetics of micafungin in neonates and young infants, Antimicrob Agents Chemother, 54, 2633, 10.1128/AAC.01679-09 Benjamin, 2006, Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections, Antimicrob Agents Chemother, 50, 632, 10.1128/AAC.50.2.632-638.2006 van Burik, 2004, Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation, Clin Infect Dis, 39, 1407, 10.1086/422312 Schonfeld, 2008, Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation, Clin Ther, 30, 964, 10.1016/j.clinthera.2008.04.020 Kusuki, 2009, Antifungal prophylaxis with micafungin in patients treated for childhood cancer, Pediatr Blood Cancer, 53, 605, 10.1002/pbc.22140 Koo, 2007, Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children, Pediatr Infect Dis J, 26, 854, 10.1097/INF.0b013e318067b4d1 Maertens, 2010, A randomized, doubleblind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia, Pediatr Infect Dis J, 29, 415, 10.1097/INF.0b013e3181da2171 Ostrosky-Zeichner, 2005, International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia, Eur J Clin Microbiol Infect Dis, 24, 654, 10.1007/s10096-005-0024-8 Queiroz-Telles, 2008, Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial, Pediatr Infect Dis J, 27, 820, 10.1097/INF.0b013e31817275e6 Odio, 2004, Caspofungin Therapy of neonates with invasive candidiasis, Pediatr Infect Dis J, 23, 1093, 10.1097/01.inf.0000145408.51526.0a Natarajan, 2005, Experience with caspofungin in the treatment of persistent fungemia in neonates, J Perinatol, 25, 770, 10.1038/sj.jp.7211380 Natarajan, 2009, Refractory neonatal candidemia and high-dose micafungin pharmacotherapy, J Perinatol, 29, 738, 10.1038/jp.2009.75 Zaoutis, 2009, A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients, Pediatrics, 123, 877, 10.1542/peds.2008-1158 Denning, 2006, Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis, J Infect, 53, 337, 10.1016/j.jinf.2006.03.003 Cesaro, 2007, Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients, BMC Infect Dis, 7, 28, 10.1186/1471-2334-7-28 Cesaro, 2004, Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis, Eur J Haematol, 73, 50, 10.1111/j.1600-0609.2004.00254.x Groll, 2006, Treatment with Caspofungin in Immunocompromised Paediatric Patients: a Multicentre Survey, J Antimicrob Chemother, 57, 527, 10.1093/jac/dkl009 Merlin, 2006, Efficacy and safety of caspofungin therapy in children with invasive fungal infections, Pediatr Infect Dis J, 25, 1186, 10.1097/01.inf.0000246844.42159.a0 Zaoutis, 2009, Safety experience with caspofungin in pediatric patients, Pediatr Infect Dis J, 28, 1132, 10.1097/INF.0b013e3181af5a15 King, 2009, Hepatitis associated with micafungin use in a preterm infant, J Perinatol, 29, 320, 10.1038/jp.2008.197 Pappas, 2009, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis, 48, 503, 10.1086/596757 Walsh, 2008, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America, Clin Infect Dis, 46, 327, 10.1086/525258